Daniel Bryce Landi MD
Medical Instructor in the Department of Pediatrics, Duke University School
Join to View Full Profile
2100 Erwin RdDurham, NC 27705
Phone+1 919-684-8111
Fax+1 919-620-4921
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Daniel Landi, MD is a pediatric hematologist/oncologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina and Texas. He is a Medical Instructor in the Department of Pediatrics at Duke University School.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2013 - 2016
Duke University HospitalResidency, Pediatrics, 2009 - 2012
University of Colorado School of Medicine Anschutz Medical CampusClass of 2009
Certifications & Licensure
NC State Medical License 2009 - 2025- NC State Medical License 2017 - 2025
TX State Medical License 2016 - 2018
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.Daniel Landi, Shoba A Navai, Rebecca M Brock, Kristen Fousek, Zeid Nawas
Cancer Research Communications. 2025-03-01 - 1 citationsRadiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof
Neuro-Oncology. 2024-12-19 - Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt
Nature Medicine. 2024-05-01
Grant Support
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastomaDUKE UNIVERSITY2021–2027
